Reported daily use
Community practice, not a measured pharmacologic interval.
Protocol / Research Dosing Guide
BPC+TB (Wolverine) Dosage Guide: Community Schedule, Reconstitution and Safety
An evidence-organized guide to the vendor-defined BPC-157 and TB-500 blend, separating community practices from component research and the unstudied combination itself.
Last reviewed September 15, 202618 minute readResearch information only
Level 1 — Blend not directly studiedCommunity protocol onlyNot FDA approved
BPC+TB (Wolverine) Quick Start
Wolverine is an informal name for a pre-mixed BPC-157 and TB-500 research product. No controlled human or animal study of this fixed blend was identified. Evidence for either component cannot be assigned to the combination.
Why researchers care
Combined repair-signaling research claims
Class
Vendor-defined BPC-157 + TB-500 blend
Route reported
Subcutaneous use is community reported
Cycle length
8 weeks reported; not validated
Regulatory status
Not FDA approved; research-use product
Loading supplier information
BPC+TB (Wolverine) Dosing Protocol and Schedule
The supplied source reports a 500 mcg total daily blend amount, plus higher community variants. Every amount, timing rule, and cycle below is vendor/community reported and has not been validated in a study of the blend.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Community standard | 500 mcg total blend | Once daily for 8 weeks; community reported |
| Community loading variant | 750 mcg total blend | Daily for 4 weeks, then 500 mcg for 8 weeks |
| Community acute variant | 500 mcg twice daily | 4 weeks, then a reported reduction |
No study establishes an appropriate human amount, frequency, cycle, rest period, or taper for BPC+TB.
BPC+TB (Wolverine) Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
BPC+TB (Wolverine) Reconstitution Calculator
Vial-format concentration math
Concentration
5 mg/mL
Draw volume
0.1 mL
U-100 units
10
Mathematical draws
20
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take BPC+TB (Wolverine): Morning or Night?
Morning or evening?
Morning use appears in community descriptions only; no preferred time is established.
Before food?
The source reports this practice, but no blend study supports a food-timing effect.
Once or twice daily?
Both patterns are community reported; neither is validated.
Missed amount?
No validated replacement or doubling instructions exist.
BPC+TB (Wolverine) Route Comparison
| Route | What is reported | Evidence limit |
|---|---|---|
| Subcutaneous | Community blend protocols | No blend-level human study |
| Oral | Not established | No blend exposure study |
| Intramuscular or intravenous | Not established | Component studies do not establish blend use |
| Route conversion | None available | Routes are not interchangeable |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
BPC+TB (Wolverine) Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Blend half-life | Not established | No combination PK study |
| BPC-157 human half-life | Not established | Animal PK cannot define human clearance |
| TB-500 fragment half-life | Not established | No formal PK study identified |
| Frequency | Daily use is community reported | Not experimentally validated |
BPC+TB (Wolverine) Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous blend | 500 mcg total | Once daily | Community report | No |
| Subcutaneous blend | 750 mcg total | Once daily | Community report | No |
| Subcutaneous blend | 1,000 mcg total | Split daily | Community report | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
BPC+TB (Wolverine) Reconstitution Guide
Concentration: 5 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 0.5 mg | 0.1 mL | 10 units |
| 1 mg | 0.2 mL | 20 units |
| 1.5 mg | 0.3 mL | 30 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How BPC+TB (Wolverine) Works
BPC-157 component
Animal studies examine tissue-repair signaling, but those findings do not test this blend.
BPC+TB (Wolverine) Human Trials and FDA Status
Current status · verified September 15, 2026
Not FDA approved; research-use product
- No controlled human trial of BPC-157 plus TB-500 was identified.
- No controlled animal study of the fixed blend was identified.
- A vendor-cited retrospective combination report could not be independently verified in major indexes.
- Component studies cannot establish combination efficacy or safety.
- The blend has no FDA-approved indication.
Who Should Avoid BPC+TB (Wolverine)?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No safety data
Children or adolescents
No safety data
Active or recent cancer
Angiogenesis-related concerns are unresolved
Bleeding or vascular disorders
No interaction or safety studies
Concurrent medicines
No interaction studies
Long-term or repeated use
No safety data
BPC+TB (Wolverine) Side Effects, Risks and Safety
Injection-site irritationCommunity reported
Important limitation: No controlled incidence data.
Nausea, lightheadedness, or fatigueCommunity reported
Important limitation: Causality is not established.
Tumor-related riskTheoretical
Important limitation: No blend carcinogenicity study.
Immune reactionUnknown
Important limitation: No characterized blend immunogenicity data.
Drug interactionsUnknown
Important limitation: No interaction studies.
Long-term effectsUnknown
Important limitation: No follow-up evidence.
BPC+TB (Wolverine) Timeline and Monitoring
Reported eight-week period
Community cycle, not a clinical treatment period.
Reported rest period
Four to eight weeks is reported; no restart criterion is established.
Monitoring
No validated biomarker panel, stopping rule, or follow-up schedule exists.
BPC+TB (Wolverine) Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Tissue repair | Not established for blend | Component animal findings and community claims | No combination study |
| Tendon or ligament recovery | Not established for blend | Primarily component animal research | No controlled human blend data |
| Inflammation | Not established for blend | Mechanistic inference | Fixed-ratio effects unknown |
| Pain improvement | Unverified report | One vendor-cited retrospective claim | Primary report not independently located |
BPC+TB (Wolverine) Storage and Handling
Unreconstituted vial
No blend-specific stability study was identified; follow the exact product label.
Prepared vial
Community refrigeration guidance is not validated stability evidence.
Mixed formulation
Co-formulation effects and degradation kinetics are not established.
Appearance
Cloudiness, discoloration, or particles do not establish sterility or usability.
BPC+TB (Wolverine) Troubleshooting
The solution looks abnormal
Stop and seek qualified product guidance; appearance cannot confirm sterility.
The units do not match another chart
Recheck total blend mg, liquid volume, entered amount, and U-100 conversion.
Per-component quantities are unclear
Do not assume a 1:1 composition unless the exact label documents it.
A component claim is presented as blend evidence
Return to the exact study product; component evidence does not transfer.
A scheduled amount is missed
No validated missed-amount procedure exists.
BPC+TB (Wolverine) Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| BPC+TB (Wolverine) | Two-component vendor blend | No direct studies | Not approved |
| BPC-157 | 15-amino-acid peptide | Mostly animal; very limited human reports | Not approved |
| TB-500 | Thymosin-related fragment | Limited and indirect evidence | Not approved |
| Klow | Four-component vendor blend | No direct studies | Not approved |
BPC+TB (Wolverine) Frequently Asked Questions
What is Wolverine?
An informal name for a vendor-defined BPC-157 and TB-500 blend.
Has the blend been studied in humans?
No controlled human blend study was identified.
Has it been studied in animals?
No controlled study of the fixed blend was identified.
Is it FDA approved?
No.
What is its half-life?
Not established.
Is the source schedule validated?
No. It is vendor/community reported.
Can BPC-157 evidence be assigned to Wolverine?
No.
Can thymosin beta-4 evidence be assigned to TB-500 or the blend?
Not automatically; the molecules and formulations differ.
Is a rest period established?
No.
What does the calculator do?
It converts entered total-vial and liquid values into concentration and volume math only.
Sources and Research
Coverage source
1. Wolverine stack dosing guide
Coverage source for community schedule and blend claims; not primary evidence.
Open direct sourceComponent animal research
2. Pharmacokinetics of BPC157 in rats and dogs
Component-only animal PK across several routes; does not test the blend.
Open direct sourceComponent animal research
3. Metabolism of acetylated thymosin beta-4 in rat urine
Doping-control metabolism research; not blend PK or a human half-life study.
Open direct sourceMissing information flagged for review
- Blend identity and pharmacology study: Not established
- Controlled human or animal blend evidence: Not established
- Human dose and route: Not established
- Blend half-life and pharmacokinetics: Not established
- Validated cycle and rest period: Not established
- Blend-specific stability: Not established
- Long-term safety: Not established
- Drug interactions: Not established